166480.KQ CORESTEM Inc

Healthcare Biotechnology KOSDAQ
1,636 KRW
Close of Oct 30, 2026
1,014 5,090
Market cap
KRW 78.7B
P/E
-
P/B
1.77x
ROE
-47.8%
Dividend yield
-
Fundamental score
0.9/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 166480.KQ undervalued?

Graham number

The Graham number of CORESTEM Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CORESTEM Inc fundamental analysis

4 of 21 checks passed

ROE 0/2

Low return on equity (-47.8%), below 10%.

ROA 0/1

Return on assets (-20.4%) is below the industry median (-10.1%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (46.2%) is above the industry median (4.8%).

Revenue Growth 0/2

Revenue shrank 24.2% a year over the past 3 years.

Short-term Liquidity 0/1

Current assets do not cover short-term liabilities.

Long-term Liabilities 0/1

Current assets do not cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (19.1%), 40% or less.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Cash Runway 0/2

Cash covers 0.5 years of the current cash burn.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 1/1

Price to book (1.8x) is below the industry median (2.4x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

CORESTEM Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CORESTEM Inc

CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and ce…

Full company profile